Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur

Cancer

Volumn 112, Issue 3, 2008, Pages 636-644

  Barbisan, Francesca ^a   Santinelli, Alfredo ^a   Mazzucchelli, Roberta ^a   Lopez Beltran, Antonio ^b   Cheng, Liang ^c   Scarpelli, Marina ^a   Van Der Kwast, Theodorus ^d   Montironi, Rodolfo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cytokeratin 20 (CK20); Fibroblast growth factor receptor 3 (FGFR3); MIB 1; Papillary urothelial neoplasm of low malignant potential; Recurrence; Urothelium

Indexed keywords

CYTOKERATIN 20; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN;

ARTICLE; CANCER RECURRENCE; CELL PROLIFERATION; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ITALY; PAPILLARY UROTHELIAL NEOPLASM OF LOW MALIGNANT POTENTIAL; PAPILLOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; UROGENITAL TRACT TUMOR; VALIDATION PROCESS;

CARCINOMA, PAPILLARY; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATIN-20; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 38749108486     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23212     Document Type: Article

References (40)

1. Sauter G, Algaba F, Amin MB, et al. Tumours of the urinary system. In: Epstein JI, Eble JN, Sesterhenn I, Sauter G, editors. World Health Organization classification of tumours pathology and genetics: tumours of the urinary system and male genital organs. Lyon, France: IARC Press; 2004:89-157.
2. Mostofi FK, Sorbin LH, Torloni. Histological typing of urinary bladder tumours: international classification of tumours. Geneva: World Health Organization; 1973.
3. Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/International Society of Urologic Pathology. Mod Pathol. 2001;14:267-272.
4. Edwards J, Duncan P, Going JJ, Watters AD, Grigor KM, Bartlett JM. Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J Pathol. 2002;196:380-385.
5. Helpap B, Kollermann J. Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution to the new WHO classification of the urothelial tumors of the urinary bladder. Hum Pathol. 2000;31:745-750.
6. Lopez-Knowles E, Hernandez S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 2006;66:7401-7404.
7. Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Navone R. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. Am J Surg Pathol. 2001;25:1528-1533.
8. Ramos D, Navarro S, Villamon R, Gil-Salom M, Llombart-Bosch A. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder. Cancer. 2003;97:1876-1883.
9. van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH, Zwarthoff EC. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet. 2000;9:2973-2980.
10. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1993;60:1-41.
11. van Rhijn BW, van Tilborg AA, Lurkin I, et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet. 2002;10:819-824.
12. Webster MK, Donoghue DJ. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet. 1997;13: 178-182.
13. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23:18-20.
14. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158:1955-1959.
15. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in non-muscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24:3664-3671.
16. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001;61:1265-1268.
17. Munro NP, Knowles MA. Fibroblast growth factors and their receptors in transitional cell carcinoma. J Urol. 2003;169:675-682.
18. De La Rosette J, Smedts F, Schoots C, Hoek H, Laguna P. Changing patterns of keratin expression could be associated with functional maturation of the developing human bladder. J Urol. 2002;168:709-717.
19. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27:1-10.
20. Christoph F, Weikert S, Wolff I, et al. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. Cancer Lett. 2007;245:121-126.
21. Harnden P, Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet. 1999;353:974-977.
22. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003;21:1912-1921.
23. Montironi R, Scarpelli M, Lopez-Beltran A, et al. Chromatin phenotype karyometry can predict recurrence in papillary urothelial neoplasms of low malignant potential. Cell Oncol. 2007;29:47-58.
24. Bernard-Pierrot I, Brams A, Dunois-Larde C, et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis. 2006;27:740-747.
25. Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 2006;25:2685-2696.
26. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, Saenz P, Martinez A, Casal JI. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res. 2005;11:6280-6290.
27. Tomlinson DC, L'Hote CG, Kennedy W, Pitt E, Knowles MA. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res. 2005;65:10441-10449.
28. van Oers JM, Lurkin I, van Exsel AJ, et al. A simple and fast method for the simultaneous detection of 9 fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005;11:7743-7748.
29. Zieger K, Dyrskjot L, Wiuf C, et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res. 2005;11:7709-7719.
30. Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene. 2001;20:4416-4418.
31. Knoles MA. The genetics of bladder cancer: molecular genetics of cancer. Oxford: Bios, 2000.
32. Mhawech-Fauceglia P, Cheney RT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer. 2006;106:1205-1216.
33. Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer. 2001;92:2555-2561.
34. Matsumoto M, Ohtsuki Y, Ochii K, et al. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions. Oncol Rep. 2004;12:967-971.
35. Gomez-Roman JJ, Saenz P, Molina M, et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res. 200515;11:459-465.
36. Mhawech-Fauceglia P, Cheney RT, Fischer G, Beck A, Herrmann FR. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol. 2006;32:231-237.
37. Harnden P, Allam A, Joyce AD, Patel A, Selby P, Southgate J. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology. 1995;27:169-174.
38. Pich A, Chiusa L, Formiconi A, et al. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer. 2002;95:784-790.
39. Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB-1 labeling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol. 2006;59:83-88.
40. van Oers JM, Wild PJ, Burger M, et al. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol. 2007;52:760-768.